Eisbach Bio is a biotechnology company that creates new drugs that target molecular vulnerabilities in cancer genomes.
Eisbach Bio has raised $4.8M in total funding. The most recent round was Grant. The last funding was announced in November 2024.
Eisbach Bio's investors include Cancer Prevention and Research Institute of Texas, Cancer Focus Fund, Pinto Ventures.
Eisbach Bio is headquartered in Munich, Germany.
Eisbach Bio is a biotechnology company that creates new drugs that target molecular vulnerabilities in cancer genomes.
Eisbach Bio is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Eisbach Bio — Funding & Investors." VCBacked, November 26, 2024, https://www.vcbacked.co/company/eisbach-bio. Accessed August 14, 2026.
VCBacked. (2024). Eisbach Bio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/eisbach-bio
{{cite web |title=Eisbach Bio — Funding & Investors |url=https://www.vcbacked.co/company/eisbach-bio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated